Fiscal 2025 results press release from iBio (NYSE: IBIO) detailed

Rhea-AI Filing Summary

iBio, Inc. filed a Form 8-K to report that it issued a press release announcing its financial results for the fiscal year ended June 30, 2025. The press release is furnished as Exhibit 99.1 to the report.

The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions and will not be incorporated by reference into other SEC filings. The report is signed on behalf of iBio by Chief Legal Counsel Marc A. Banjak.

0001420720false00014207202025-09-052025-09-05

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 5, 2025

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

​	​
001-35023	26-2797813
(Commission File Number)	(IRS Employer Identification No.)

​

11750 Sorrento Valley Road, Suite 200

San Diego, California 92121

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​	​	​
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

​

​

​

Item 2.02.      Results of Operations and Financial Condition.

​

On September 5, 2025, iBio, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal year ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

​

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

​

Item 9.01.      Financial Statements and Exhibits.

(d)      Exhibits.

The following exhibit is furnished with this Current Report on Form 8-K.

​	​	​
Exhibit Number		Exhibit Description
99.1	​	Press Release, issued by iBio, Inc. dated September 5, 2025
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

Date: September 5, 2025	IBIO, INC.
​
​	By:	/s/ Marc A. Banjak
​	​	Name: Marc A. Banjak
​	​	Title: Chief Legal Counsel

​

​

FAQ

What did iBio (IBIO) disclose in this Form 8-K?

iBio filed a Form 8-K stating that it issued a press release announcing its financial results for the fiscal year ended June 30, 2025, which is furnished as Exhibit 99.1.

Which period’s results does iBio’s press release cover?

The press release furnished with the Form 8-K covers iBio’s financial results for the fiscal year ended June 30, 2025.

How is the information in iBio’s Exhibit 99.1 treated under securities laws?

iBio specifies that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, so it is not subject to Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act and will not be incorporated by reference into other SEC filings.

What exhibits are included with this iBio (IBIO) Form 8-K?

The Form 8-K includes Exhibit 99.1, a press release dated September 5, 2025, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

Who signed this iBio Form 8-K and in what capacity?

The Form 8-K was signed on behalf of iBio, Inc. by Marc A. Banjak, who is identified as the company’s Chief Legal Counsel.

Where is iBio’s principal executive office located according to this filing?

According to the filing, iBio’s principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.